ArticleHaematologica2026

Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMSlike tyrosine kinase 3 internal tandem duplication.

Sonia Jaramillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.